1. Introduction
===============

*Acinetobacter baumannii*, a gram-negative coccobacillus, is a nosocomial pathogen that has emerged as a major cause of infection in critical patients with suppressed immunity, major trauma, or burns.^\[[@R1]--[@R4]\]^ Because of the inappropriate use of broad-spectrum antibiotics in empirical treatment of nosocomial infections, there have been outbreaks of pan-drug-resistant *A baumannii* (PDRAB) infections all over the world over the past 20 years or more.^\[[@R5],[@R6]\]^ The rapid emergence of pan-drug-resistant in Acinetobacter genomic species makes PDRAB infections are difficult to treat.^\[[@R5]\]^ Thus, there is an urgent need to develop effective antimicrobial agents against emerging PDRAB.

Antimicrobial peptides (AMPs) are a part of the host defense generated by a wide variety of organisms and act as an important component of innate immunity.^\[[@R8],[@R9]\]^ Cathelicidins are one of several families of AMPs that are found in humans and other species, such as cattle, horses, and pigs.^\[[@R10]\]^ A bovine myeloid antimicrobial peptide (BMAP-28) belongs to the cathelicidin family and exerts potent antimicrobial activity in order to protect animals from bacterial and fungal infections.^\[[@R11]\]^ Brogden et al^\[[@R12]\]^ report that BMAP-28 has antimicrobial activity against *Pasteurella multocida*. Takagi et al^\[[@R13]\]^ describe the antimicrobial activity of BMAP-28 and its analogs against methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* (MRSA) and Lynn et al^\[[@R14]\]^ show the antimicrobial effects of BMAP-28 on *Leishmania* growth. Moreover, it has been indicated that the antimicrobial effect of BMAP-28 can be enhanced by altering its cationic and hydrophobic amino acid residues. To assess this possibility, we have designed 4 analogs of BMAP-28, A837, A838, A839, and A840, which possess a different positive charge when compared to BMAP-28. In the current study, BMAP-28 and its 4 analogs were tested to determine their antimicrobial effects against PDRAB. Specifically, the effect of these peptides on bacterial cell integrity and bacterial activity was assessed.

Moreover, previous researchers have found the AMPs interact with negatively charge outer membrane proteins (OMPs) of bacteria,^\[[@R15],[@R16]\]^ leading to a destabilization and permeabilization of the cell membrane and leakage of the cell contents. It has been reported that the outer membrane protein A of *A baumannii* (AbOmpA), which is a multifunctional protein, is involved in eukaryotic cell adhesion, invasion, biofilm formation, and apoptosis.^\[[@R7],[@R17]\]^ Here, the interaction between BMAP-28 and AbOmpA was determined by quartz crystal microbalance (QCM) analysis in order to understand the possible inhibitory mechanism of BMAP-28 on PDRAB.

2. Materials and methods
========================

2.1. Bacterial strains and ethics approval
------------------------------------------

Ten strains of PDRAB were isolated from the skin swabs of ten separate patients with wound infection at the First Affiliated Hospital of Xi'an Jiao Tong University according to the guidelines of the Centers for Disease Control and Prevention (CDC). The isolates were identified using the VITEK 2 system (bioMérieux, Marcy l'Etoile, France) and further confirmed using specific PCR with primers sp2F, sp4F, and sp4R. Antibiotics susceptibility testing was performed using VITEK 2 system. PDRAB isolates are resistant to all antibiotics, including the carbapenems, while sensitive to colistin. The ATCC standard strain of *A baumannii* (19606) was used as a positive control. The bacteria were cultured in brain heart infusion broth (BHI; OXOID, Hampshire, UK) at 37 °C for 24 hours. All experiments were carried out in accordance with the ethical standards of the Helsinki declaration and were approved by the ethics committee of the medical school of Xi'an Jiao Tong University.

2.2. Synthesis of BMAP-28 and its analogs
-----------------------------------------

BMAP-28 and its 4 analogs (A837, A838, A839, and A840) were synthesized as previously described by Isogai et al.^\[[@R18]\]^ Each of the 4 analogs differs from the original BMAP-28 sequence by one to 3 amino acid residues and has a net charge ranging from +7 to +9. Their sequences are shown in Table [1](#T1){ref-type="table"}. These peptides were purified by reverse-phase high-performance liquid chromatography with purity levels over 98%. The final products were identified by electrospray ionization mass spectrometry, suspended in Hank\'s balanced salt solution, and stored at −80 °C.

###### 

Amino acid sequences and physical information of BMAP-28 and its 4 analogs.
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2.3. Bacterial growth inhibition test
-------------------------------------

The optical density (OD) at 595 nm of the precultured bacteria was measured using SkanIt software. The bacterial suspension was diluted to an OD595 of 0.02 and then further diluted to a final concentration of 10^3^ to 10^4^ CFU/mL in BHI broth. The peptide solution was prepared by 2-fold serial dilutions in BHI broth. Next, 1 mL of adjusted bacteria and 1 mL of peptide solution were mixed and incubated at 37 °C. The bactericidal activity of each peptide was evaluated by measuring the minimum inhibitory concentration (MIC) over 24 hours.^\[[@R19]\]^

2.4. Short time killing assay
-----------------------------

PDRAB suspension was inoculated to a final concentration of 1 × 10^4^ cells/mL into 100 μL of sodium phosphate buffer (PBS) in the presence or absence of 40 μg/mL BMAP-28, A837, A838, A839, or A840 and then incubated aerobically for 15, 30, or 60 minutes at 37 °C. The bacterial mixtures were then diluted and inoculated onto BHI agar plates and the CFU was calculated for each. A control group was prepared by plating the reaction mixture that had not received peptide treatment.

2.5. Field emission scanning electron microscopy (FE-SEM)
---------------------------------------------------------

Ten microliters of BMAP-28 (80 μg/mL) and 10 μL of bacterial suspension were placed on a glass slide and incubated at 37 °C for 15, 30, and 60 minutes, and then air-dried for a minimum of 24 hours. After being dried, the slide was saturated first with 70% ethanol for 5 minutes and then 100% ethanol for 5 minutes. The slide was then coated with a palladium alloy and observed by FE-SEM (SU8000; HITACHI, Tokyo, Japan) in order to assess the effect of BMAP-28 on PDRAB.

2.6. Extraction of *A baumannii* outer membrane proteins (AbOMPs) and preparation of AbOmpA
-------------------------------------------------------------------------------------------

Extraction of AbOMPs was performed according to the method previously described by Cuenca et al.^\[[@R20]\]^ Briefly, overnight cultures of *A baumannii* were subcultured into 100 mL of LB medium and cultured at 37 °C overnight. Cell pellets were centrifuged at room temperature and washed with PBS twice. The cells pellets were then resuspended in 20 mL of 10 mM phosphate buffer (pH 7.2) with 1 mM PMSF. The cells were destroyed by sonication for 12 min on ice. To extract the proteins, the cell debris was isolated by centrifugation and then the supernatant was collected. The supernatant was solubilized using 2% sodium lauryl sarcosinate in 10 mM phosphate buffer for 30 min at room temperature. Finally, AbOMPs were centrifuged, re-suspended in 62.6 mM Tris--HCl buffer, and stored at −20 °C.

AbOmpA was kindly given from Dr Lei (Xi'an Jiaotong University, Xi'an, China). The preparation of AbOmpA was described as following: full-length AbOmpA gene (1317 bp) was amplified by PCR. A chromosomal preparation of *A baumannii* ATCC 19606T was used as a PCR substrate. The upstream primer 5′-ACAGGATCCATGAAATTGAGTCGTATT-3′ was designed to carry BamHI restriction site and the downstream primer 5′ -ACAAGCTTTTATTGAGCTGCTGCA-3′ carried the HindIII restriction site. PCR products digested with BamHI and HindIII were ligated into the pET28a expression vector (Novagen). *Escherichia coli* BL21 (DE3)/pET28a harboring a ompA gene was grown in LB medium at 37 °C and recombinant proteins were overexpressed with 1 mM IPTG at 25 °C for 4 hours. After sonication of bacterial cells, the pellet containing the inclusion bodies was discarded and the supernatant containing the soluble form of AbOmpA was collected by centrifugation. The protein samples were loaded on a 5 ml HiTrapTM FF column (Amersham Biosciences) equilibrated with binding buffer (20 mM sodium phosphate, 500 mM NaCl and 5 mM imidazole). His-tagged OmpA was eluted by elution buffer (20 mM sodium phosphate, 500 mM NaCl and 500 mM imidazole). The samples were massively dialyzed against elution buffer without imidazole and then dialyzed with phosphate-buffered saline (PBS, pH 7.4) to reduce salt concentrations. AbOmpA was incubated with endotoxin removal resin for overnight to remove LPS and concentrated by Centricon (2,000 MW cut-off; Millipore). AbOmpA was analyzed for purity by SDS--PAGE after denaturation with sample buffer (60 mM Tris--HCl, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, and 0.1% bromophenol blue) at 100 °C for 5 minutes. After electrophoresis, the gels were stained with 0.1% (w/v) Coomassie blue. Also, endotoxin was assayed under endotoxin-free experimental conditions using a Limulus Amebocytes Lysate (LAL) pyrogen kit (Biowhittaker, Walkersville, MD). The experiments were conducted according to the manufacturer\'s protocol.

2.7. Western blotting analysis
------------------------------

AbOMPs or AbOmpA (20 μg/lane) were mixed with sample buffer and heated at 100°C for 10 minutes, and then separated by 12% SDS-PAGE and transferred to a PVDF membrane (Bio-Rad Laboratories, Hercules, CA). After incubation in 3% skim milk blocking solution, the membrane was probed overnight at 4°C using anti-OmpA (1:5000; a kind gift from Dr Liu Xi'an Jiaotong University, Xi'an, China). Subsequently, the membrane was incubated at room temperature for 1 h with HRP-labeled goat anti-rabbit IgG (Merck-Millipore, Darmstadt, Germany; 1:10,000), and the immunoreactivities were visualized by reacting with enhanced chemiluminescence (ECL) solution (Beyotime, Shanghai, China). The photos were taken with a Fusion FX5 camera system, and the densities of the protein bands were analyzed using Image J software (National Institute of Health, Bethesda, MA).

2.8. Quartz crystal microbalance (QCM)
--------------------------------------

BMAP-28 containing an additional C-terminal cysteine was used as a ligand and OmpA from *A baumannii* as a receptor. QCM measurements were performed with an AFFINIX QN. The quartz crystal sensor surfaces were washed 2 times with concentrated sulfuric acid and hydrogen peroxide solution (3:1) for 5 min. Immobilization of the receptor was achieved using the AFFINIX kit according to the method described by Lahiri et al.^\[[@R21]\]^ After BMAP-28 was bound to the sensor, 5 μL of OmpA solution was applied. OmpA bound to the blocking agent was used as a control at 1 μg/mL. All of these experiments were conducted at 25 °C.

2.9. Statistical analysis
-------------------------

Three independent experiments were performed for each batch of bacterial cells. Results are presented as mean ± standard deviation. The *p* value was calculated using Dunnett\'s test. *P \< *.05 was considered to be statistically significant.

3. Results
==========

3.1. Antimicrobial activity of BMAP-28 and its analogs on the growth of PDRAB
-----------------------------------------------------------------------------

The growth inhibition of PDRAB with the treatment of peptides was show in the Supplementary Table 1. The MICs for 10 clinical strains of PDRAB were calculated at 5--10, 20, 5--20, 5--20, and 5--20 μg/mL for BMAP-28, A837, A838, A839, and A840 treatment, respectively (Table [2](#T2){ref-type="table"}). For the standard strain of PDRAB, the MICs were calculated at 5, 10, 5--10, 5--10, and 5--10 μg/mL for BMAP-28, A837, A838, A839, and A840, respectively (Table [2](#T2){ref-type="table"}).
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Growth inhibition of pan-drug-resistant *Acinetobacter baumannii* by the treatment of BMAP-28 and its analogs.
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3.2. The short-time antibacterial effect of BMAP-28 and its analogs on the growth of PDRAB
------------------------------------------------------------------------------------------

To determine the short time kinetics of the antimicrobial effect of BMAP-28 and its 4 analogs against PDRAB, bacterial suspensions were incubated with 40 μg/mL of peptide for 15, 30, or 60 min. All 5 peptides demonstrated time-dependent antibacterial effects against PDRAB (Fig. [1](#F1){ref-type="fig"}), with bacterial cells being rapidly killed by BMAP-28 after only 15 mins of incubation. While each of the 4 analogs showed only a minimal effect against bacterial cells when compared to untreated cells, they all showed a gradually reduced trend with the treatment time. The effectiveness of each peptide against PDRAB was ranked as BMAP-28 \> A837 \> A838 \> A839 \> A840.

![Short-time bactericidal effect of BMAP-28 and its analogs against pan-drug-resistant *Acinetobacter baumannii*. Data were mean ± SD of 3 independent experiments. ^∗^, statistical significance different compared with untreated control (*P \< *.05). ^∗∗^, statistical significance different compared with untreated control (*P \< *.01).](medi-97-e12832-g003){#F1}

3.3. The effect of BMAP-28 on the cell surface of PDRAB
-------------------------------------------------------

The effect of BMAP-28 (40 μg/mL) treatment on the cell morphology of PDRAB after 15, 30, or 60 min were observed using FE-SEM. As shown in Figure [2](#F2){ref-type="fig"}C, the cell morphology changed at 30 minutes with the treatment of BMAP-28, the cell spherical ratio showed an obvious decrease in compared with untreated control. In Figure [2](#F2){ref-type="fig"}D, some of the bacterial cells treated with BMAP-28 appear to be broken and leaking cytoplasm. Additionally, the surface appears rough compared to untreated PDRAB cells (Fig. [2](#F2){ref-type="fig"}A), which appear to have mostly smooth outlines and are not aggregated.

![Bacteria cell surface damage after treatment with BMAP-28. The pictures (A--D) are bacteria cells of PDRAB observed by field emission scanning electron microscope after co-culturing with 80 μg/mL BMAP-28 for 0, 15, 30, and 60 minutes, respectively. BMAP-28 = bovine myeloid antimicrobial peptide.](medi-97-e12832-g004){#F2}

3.4. *A baumannii* OmpA is the main component of *A baumannii* OMPs
-------------------------------------------------------------------

To verify OmpA is a major porin protein in the OMPs of *A baumannii*, we observed the composition of AbOMPs by Coomassie blue staining (Fig. [3](#F3){ref-type="fig"}). The OmpA with a molecular mass of 38 kDa showed the strongest signal in the total OMPs of *A baumannii* by Coomassie blue staining and verified by western blotting analysis with the anti-OmpA antibody. Here, we use the purified OmpA as a positive control.

![The main component of *A baumannii* OMPs (AbOMPs). The purificated AbOMPs and AbOmpA were analyzed by electrophoresis, and stained with Coomassie blue (Lane 1 and Lane 2). AbOMPs and AbOmpA in another gel were transferred onto a PVDF membrane and blotted with an anti-OmpA antibody (Lane 3 and Lane 4). The signals were detected using enhanced chemiluminescence (ECL). AbOmpA = *Acinetobacter baumannii* OmpA, ECL = enhanced chemiluminescence.](medi-97-e12832-g005){#F3}

3.5. BMAP-28 interacts with the *A baumannii* OmpA
--------------------------------------------------

Because BMAP-28 can inhibit PDRAB growth, we considered that the mode of action may through the interaction of BMAP-28 and PDRAB. Thus, we were interested in identifying potential target for BMAP-28 on the cell surface, especially on the PDRAB outer membrane proteins (OMPs). In this study, we analyzed the interaction of BMAP-28 and AbOMPs by using QCM. Based on the QCM data by plotting the observed frequency shifts in Figure [4](#F4){ref-type="fig"}, OMPs (1 μg/mL) bound to the blocking agent, as a negative control, showed an insignificant reduction (12 Hz) in the measured frequency. While, OMPs bound to BMAP-28 showed obvious decreases of frequency, the levels of frequency decrease were 198, 427 and 645 Hz after injection of 0.5, 1.0, and 2.0 mg/mL OMPs, respectively. We also analyzed the interaction of BMAP-28 and AbOmpA by using QCM. The level of frequency decrease caused by AbOmpA (1 μg/mL) bound to BMAP-28 was 409 Hz.

![Interaction between BMAP-28 and AbOMPs or AbOmpA. The graphs show the change of delta frequency after injecting AbOMPs or AbOmpA on the sensor of quartz crystal microbalance (QCM). Around 5 μL of AbOMPs (the final concentrations were 0.5, 1.0 and 2.0 μg/mL) or AbOmpA (the final concentrations were 1.0 μg/mL) was injected, respectively. OmpA without the binding of BMAP-28 was injected on the sensor as a control. This graph is one of the most typical data which have done 3 times. AbOmpA = *Acinetobacter baumannii* OmpA, BMAP-28 = bovine myeloid antimicrobial peptide, QCM = quartz crystal microbalance.](medi-97-e12832-g006){#F4}

4. Discussion
=============

With the inappropriate usage of broad-spectrum antibiotics and the versatile genetic machinery of PDRAB, outbreaks of pan-drug-resistant *A baumannii* have become a significant public health threat. Currently, effective treatments for PDRAB infection are limited. Thus, the development of new and effective agents to inhibit PDRAB growth is urgent. In this study, the antimicrobial activity of BMAP-28 and its 4 analogs against PDRAB was examined. We found no significant difference between the MIC of BMAP-28 and its analog peptides. In the short time killing assay, BMAP-28 and its analogs demonstrated rapid killing of PDRAB within 60 min, with the effects of BMAP-28 occurring more quickly than those for its analog peptides. The antimicrobial effect of BMAP-28 against PDRAB did not improve with increased net charge, as seen in A837, A838, and A840; this indicates that there might be a critical threshold of positive charge density or net positive charge on BMAP-28 that governs its antimicrobial activities. ^\[[@R22],[@R23]\]^

Based on the average hydrophobicity, only A839 had a higher value than BMAP-28, with no significant differences observed between the other peptides. Takagi et al. reported that substituting a small number of amino acids on BMAP-28 did not affect its antimicrobial activity against MSSA and MRSA.^\[[@R24]\]^ This indicates that there might be an optimal hydrophobicity window to obtain the antimicrobial activity of AMPs, which may be dramatically compromised by decreases or increases in hydrophobicity.^\[[@R9]\]^

Furthermore, we found that BMAP-28 has the potential to kill PDRAB through disruption of the integrity of bacterial membranes, as seen under FE-SEM observation. Most studies exhibit that AMPs act on gram-negative bacteria through their surface lipopolysaccharide (LPS) molecules.^\[[@R25]--[@R27]\]^ A previous study reported that LL-37 may bind to *A baumannii* LPS with high affinity, but its bactericidal activity is not LPS-dependent.^\[[@R28]\]^ However, several studies have emphasized the interaction between AMPs and bacterial outer membrane proteins (OMPs). OprI of *Pseudomonas aeruginosa* has been shown to be the target of cationic AMPs,^\[[@R16]\]^ while OmpF from *E coli* and lipoteichoic acid (LTA) from *Staphylococcus aureus* cell walls have been observed to interact with cationic AMPs.^\[[@R29],[@R30]\]^ OmpA is an outer membrane porin protein that has a highly conserved amino acid sequence among gram-negative bacteria.^\[[@R31]\]^ It has been reported that OmpA from *A baumannii* can interact with LL-37.^\[[@R32]\]^ To understand the possible killing mechanism of BMAP-28 against PDRAB in this study, we isolated OMPs from PDRAB and found their interaction with BMAP-28 through QCM analysis, and furthermore we purified OmpA from PDRAB and found that it can interact with BMAP-28. Based on the above results, our study suggests that OmpA from PDRAB can act as a receptor for BMAP-28 and may involve in the bacteria-killing effect of BMAP-28 on PDRAB.

There were some limitations to this study. First, the contribution of OmpA to BMAP-28 action in PDRAB was not understood clearly. Second, the contribution of other bacterial cell surface molecules, especially LPS, to BMAP-28 action in PDRAB deserved further investigation. Therefore, we hope to use the *ompA* deletion strain and LPS-deficient *A baumannii* to further investigate the contribution of OmpA and LPS to BMAP-28 action in PDRAB.

In conclusion, we have compared the effects of BMAP-28 and its analog peptides against PDRAB and determined that the amino acid substitutions present in the analog peptides do not improve antimicrobial activity. We also observed the damaging effect of BMAP-28 on the cell morphology of PDRAB, and additionally found that BMAP-28 can interact with OmpA of PDRAB which may be related with the bacteria-killing effect of BMAP-28. In this study, it suggests that BMAP-28 and its analogs may provide effective, alternative treatments for PDRAB infections.
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